Brexpiprazole (Rexulti): A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder.

Article Details

Citation

Copy to clipboard

Eaves S, Rey JA

Brexpiprazole (Rexulti): A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder.

P T. 2016 Jul;41(7):418-22.

PubMed ID

27408517 [ View in PubMed

]

Abstract

Brexpiprazole (Rexulti): a new monotherapy for schizophrenia and adjunctive therapy for major depressive disorder.

DrugBank Data that Cites this Article

Drugs

Brexpiprazole

Drug Interactions

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drugs	Interaction
Integrate drug-drug interactions in your software
Brexpiprazole Seproxetine	The metabolism of Brexpiprazole can be decreased when combined with Seproxetine.
Brexpiprazole Cyclosporine	The metabolism of Brexpiprazole can be decreased when combined with Cyclosporine.
Brexpiprazole Clozapine	The metabolism of Brexpiprazole can be decreased when combined with Clozapine.
Brexpiprazole Nicardipine	The metabolism of Brexpiprazole can be decreased when combined with Nicardipine.
Brexpiprazole Isoniazid	The metabolism of Brexpiprazole can be decreased when combined with Isoniazid.